Safety report. An overview of all AEs is given in (a), whereas in (b), the intensity of all AEs in the patient population is shown. Percentages are based on the total number of patients (n = 294). 1AEs were considered to be related to IFX or not judged. AEs, adverse events; IFX, infliximab; SAEs, serious adverse events.